{"id":29196,"date":"2022-04-08T16:03:12","date_gmt":"2022-04-08T14:03:12","guid":{"rendered":"https:\/\/www.cmtc.nl\/blog\/2022\/04\/08\/goedkeuring-alpelisib-door-fda\/"},"modified":"2025-02-25T16:05:56","modified_gmt":"2025-02-25T15:05:56","slug":"approval-alpelisib-by-fda","status":"publish","type":"post","link":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/","title":{"rendered":"Approval alpelisib by FDA"},"content":{"rendered":"<p>Novartis\u2019 medicine Vijoice\u00ae (alpelisib) has recently (6 April) been approved by the US Food and Drug Administration (FDA) for the treatment of patients aged two years and older with severe manifestations of PIK3CA-related overgrowth syndrome (PROS). Until today, the only treatment options for these patients are surgical or interventional radiology procedures.<\/p>\n<p><a href=\"https:\/\/www.cmtc.nl\/en\/pedia\/pedia-other\/alpelisib-approved-by-fda-for-treatment-of-pros\/\" target=\"_blank\" rel=\"noopener\">More information<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis\u2019 medicine Vijoice\u00ae (alpelisib) has recently (6 April) been approved by the US Food and Drug Administration (FDA) for the treatment of patients aged two years and older with severe manifestations of PIK3CA-related overgrowth syndrome (PROS). Until today, the only treatment options for these patients are surgical or interventional radiology procedures. More information<\/p>\n","protected":false},"author":2,"featured_media":2378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[297],"tags":[],"class_list":["post-29196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Approval alpelisib by FDA - CMTC-OVM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Approval alpelisib by FDA - CMTC-OVM\" \/>\n<meta property=\"og:description\" content=\"Novartis\u2019 medicine Vijoice\u00ae (alpelisib) has recently (6 April) been approved by the US Food and Drug Administration (FDA) for the treatment of patients aged two years and older with severe manifestations of PIK3CA-related overgrowth syndrome (PROS). Until today, the only treatment options for these patients are surgical or interventional radiology procedures. More information\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"CMTC-OVM\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-08T14:03:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-25T15:05:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lex van der Heijden\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lex van der Heijden\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\"},\"author\":{\"name\":\"Lex van der Heijden\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f\"},\"headline\":\"Approval alpelisib by FDA\",\"datePublished\":\"2022-04-08T14:03:12+00:00\",\"dateModified\":\"2025-02-25T15:05:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\"},\"wordCount\":57,\"image\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg\",\"articleSection\":[\"Latest news\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\",\"url\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\",\"name\":\"Approval alpelisib by FDA - CMTC-OVM\",\"isPartOf\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg\",\"datePublished\":\"2022-04-08T14:03:12+00:00\",\"dateModified\":\"2025-02-25T15:05:56+00:00\",\"author\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage\",\"url\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg\",\"contentUrl\":\"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cmtc.nl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Approval alpelisib by FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/#website\",\"url\":\"https:\/\/www.cmtc.nl\/en\/\",\"name\":\"CMTC-OVM\",\"description\":\"Global non-profit patient organisation\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cmtc.nl\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f\",\"name\":\"Lex van der Heijden\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g\",\"caption\":\"Lex van der Heijden\"},\"description\":\"Father of a daughter with CMTC. Founder and President of the CMTC-OVM organisation. Former Senior Project Manager IBM Global Services.\",\"sameAs\":[\"https:\/\/www.cmtc.nl\/\"],\"url\":\"https:\/\/www.cmtc.nl\/en\/blog\/author\/lex\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Approval alpelisib by FDA - CMTC-OVM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/","og_locale":"en_US","og_type":"article","og_title":"Approval alpelisib by FDA - CMTC-OVM","og_description":"Novartis\u2019 medicine Vijoice\u00ae (alpelisib) has recently (6 April) been approved by the US Food and Drug Administration (FDA) for the treatment of patients aged two years and older with severe manifestations of PIK3CA-related overgrowth syndrome (PROS). Until today, the only treatment options for these patients are surgical or interventional radiology procedures. More information","og_url":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/","og_site_name":"CMTC-OVM","article_published_time":"2022-04-08T14:03:12+00:00","article_modified_time":"2025-02-25T15:05:56+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg","type":"image\/jpeg"}],"author":"Lex van der Heijden","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lex van der Heijden","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#article","isPartOf":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/"},"author":{"name":"Lex van der Heijden","@id":"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f"},"headline":"Approval alpelisib by FDA","datePublished":"2022-04-08T14:03:12+00:00","dateModified":"2025-02-25T15:05:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/"},"wordCount":57,"image":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg","articleSection":["Latest news"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/","url":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/","name":"Approval alpelisib by FDA - CMTC-OVM","isPartOf":{"@id":"https:\/\/www.cmtc.nl\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage"},"image":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg","datePublished":"2022-04-08T14:03:12+00:00","dateModified":"2025-02-25T15:05:56+00:00","author":{"@id":"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f"},"breadcrumb":{"@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#primaryimage","url":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg","contentUrl":"https:\/\/www.cmtc.nl\/wp-content\/uploads\/2020\/04\/pills.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/04\/08\/approval-alpelisib-by-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cmtc.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Approval alpelisib by FDA"}]},{"@type":"WebSite","@id":"https:\/\/www.cmtc.nl\/en\/#website","url":"https:\/\/www.cmtc.nl\/en\/","name":"CMTC-OVM","description":"Global non-profit patient organisation","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cmtc.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.cmtc.nl\/en\/#\/schema\/person\/fae194c6ccc4c847d931396c118a0b7f","name":"Lex van der Heijden","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/048d3445f0c653122a4ffb542f66ffe120bde7d60ba1496b6bac440d25817b8d?s=96&d=mm&r=g","caption":"Lex van der Heijden"},"description":"Father of a daughter with CMTC. Founder and President of the CMTC-OVM organisation. Former Senior Project Manager IBM Global Services.","sameAs":["https:\/\/www.cmtc.nl\/"],"url":"https:\/\/www.cmtc.nl\/en\/blog\/author\/lex\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/posts\/29196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/comments?post=29196"}],"version-history":[{"count":3,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/posts\/29196\/revisions"}],"predecessor-version":[{"id":64013,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/posts\/29196\/revisions\/64013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/media\/2378"}],"wp:attachment":[{"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/media?parent=29196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/categories?post=29196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cmtc.nl\/en\/wp-json\/wp\/v2\/tags?post=29196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}